GlassScriptPhysician profile
Henrik O Berdel
NPI 1740501345
$2,879.56
in general payments reported to CMS, 2019-2025
14 companies · $41.78 in 2025
The $41.78 reported for 2025 was less than what a typical Surgical Critical Care provider received nationally (typical 2025 total: $234).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $237 · 2021: $278 · 2022: $624 · 2023: $944 · 2024: $441 · 2025: $41.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,407 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,406.73 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $1,111.18 | 2022-2025 | Phasix Mesh, Xenmatrix Ab Surgical Graft |
| Atricure, INC. | $584.40 | 2021-2023 | |
| Boston Scientific Corporation | $296.40 | 2021-2024 | Spyglass Discover |
| Bard Peripheral Vascular, INC. | $171.46 | 2019-2020 | |
| Tactile Systems Technology INC | $116.30 | 2019-2020 | |
| Solventum Corporation | $106.25 | 2024-2025 | V.A.C.Ulta, V.A.C. Veraflo, Prevena |
| Cardiovascular Systems INC. | $96.96 | 2020 | |
| Getinge USA Sales, LLC | $94.67 | 2019 | |
| Tela Bio, INC. | $84.21 | 2024 | Ovitex 2s |
| Endologix LLC | $71.89 | 2019 | |
| Depuy Synthes Sales INC. | $65.61 | 2023 | Matrixrib |
| Teleflex LLC | $32.33 | 2022-2023 | Quikclot |
| Astrazeneca Pharmaceuticals LP | $27.90 | 2024 | Andexxa |
| Csl Behring | $20.00 | 2024 | Kcentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henrik Berdel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.